In recent years, the traditional binary classification of breast cancer as either HER2-positive or HER2-negative has been increasingly questioned, especially in light of new evidence supporting the effectiveness of HER2-targeting ADCs in patients with metastatic HER2-low breast cancer [7,11]. Here, ERBB2 is linked to breast carcinoma.